Skip to content
Clinical Trials – home

Pneumococcal polysaccharide serotype 19F: clinical trials in pneumococcal infections

0 / 1
trials open to patients / all trials
2+
Countries

In short

Pneumococcal polysaccharide serotype 19F is a component of the authorised pneumococcal conjugate vaccine Synflorix, which is given to protect against infections caused by the bacterium Streptococcus pneumoniae. One completed Phase 2 clinical trial in the EU registry investigated a monovalent pneumococcal conjugate candidate containing this serotype in 100 healthy toddlers. The trial assessed safety and immunogenicity, focusing on local and systemic reactions after vaccination.

Key points

  • Phase 2 trial of a monovalent pneumococcal conjugate candidate in healthy toddlers aged 11 to 15 months.
  • The trial enrolled 100 participants and has been completed.
  • Pneumococcal polysaccharide serotype 19F is part of the authorised vaccine Synflorix, used against pneumococcal infections.
  • The trial measured prompted local reactions such as redness, swelling and pain, plus systemic events like fever and irritability.
  • The vaccine is given as a 0.5 ml suspension for injection into the muscle.
  • Synflorix is authorised in the EU and supplied by GlaxoSmithKline Biologicals S.A.

What is pneumococcal polysaccharide serotype 19F?

Pneumococcal polysaccharide serotype 19F conjugated to diphtheria toxoid carrier protein adsorbed on aluminium phosphate is one of ten pneumococcal polysaccharide serotypes contained in the authorised vaccine Synflorix. Synflorix is a pneumococcal polysaccharide conjugate vaccine (adsorbed) supplied as a suspension for injection in a pre-filled syringe. The vaccine is authorised in the European Union and is held by GlaxoSmithKline Biologicals S.A. In the EU clinical trial registry, the substance appears as an auxiliary medicine in six trial records, meaning it is used as a supporting or comparison product rather than the main investigational substance.

How does pneumococcal polysaccharide serotype 19F work?

Pneumococcal conjugate vaccines contain polysaccharides from the surface of Streptococcus pneumoniae bacteria, chemically linked (conjugated) to a carrier protein. In Synflorix, serotype 19F is conjugated to a diphtheria toxoid carrier protein and adsorbed on aluminium phosphate. The body is expected to develop an immune response against the injected serotypes, which would help in prevention of disease caused by Streptococcus pneumoniae. The carrier protein enhances the immune response, particularly in young children whose immune systems respond less well to plain polysaccharides.

Which conditions is pneumococcal polysaccharide serotype 19F used or studied for?

  • Pneumococcal infections — infections caused by Streptococcus pneumoniae, which can include pneumonia, meningitis and sepsis. The clinical trial investigated prevention of these infections in healthy toddlers.
  • Respiratory tract diseases — the therapeutic area of the trial records includes respiratory tract diseases, reflecting the role of pneumococcal vaccines in preventing respiratory infections.

How is pneumococcal polysaccharide serotype 19F given?

Synflorix is given as a 0.5 ml suspension for injection by intramuscular use. Each 0.5 ml dose contains 3 micrograms of pneumococcal polysaccharide serotype 19F conjugated to diphtheria toxoid carrier protein (3 to 6 micrograms) and adsorbed on aluminium phosphate. The vaccine is supplied in pre-filled syringes and vials, in pack sizes of 1, 10, 50 or 100 units. In the Phase 2 trial, the monovalent candidate containing serotype 19F was given as a 0.5 ml intramuscular injection.

What do the clinical trials show?

The EU clinical trial registry contains one completed Phase 2 trial that included pneumococcal polysaccharide serotype 19F as part of a monovalent pneumococcal conjugate candidate in healthy toddlers. The trial enrolled 100 children aged 11 to 15 months and investigated the safety and immunogenicity of the candidate when administered as a 2-dose series.

The primary outcomes measured were prompted local reactions at the injection site (redness, swelling and pain), prompted systemic events (fever, decreased appetite, drowsiness or increased sleep, and irritability), adverse events and serious adverse events. The trial status is completed, meaning the study has finished and results are being or have been analysed.

What side effects are known?

The most common adverse events reported with pneumococcal conjugate vaccines include injection site pain or tenderness. Other common systemic adverse events reported are fever and injection site redness. There is a remote chance of a severe allergic reaction, which may very rarely occur after a dose. Signs of a severe allergic reaction can include difficulty in breathing and rash all over the body.

Questions people often ask

Conditions where PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO DIPHTHERIA TOXOID CARRIER PROTEIN ADSORBED ON ALUMINIUM PHOSPHATE is being studied

Each condition opens its own overview and trial list

Trials with PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19F CONJUGATED TO DIPHTHERIA TOXOID CARRIER PROTEIN ADSORBED ON ALUMINIUM PHOSPHATE

Recruiting trials first

See all 1 →
Quick filters
  • Participants:Children · Healthy volunteers
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.